Compare Mesoblast Limited (MESO) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs 3M Company — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while 3M Company trades at $163.61 (market cap $83.61B). The key difference: 3M Company is far larger — about 46.2× Mesoblast Limited's market cap, and 3M Company pays a 1.92% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and 3M Company for 169 Days on average.
| MESO | MMM | |
|---|---|---|
Market Cap | $1.81B | $83.61B |
Volume | 240,620 | 3,188,723 |
Sector | Health | Industrials |
52-Week High | $20.96 | $183.79 |
52-Week Low | $13.19 | $141.10 |
Typical Hold Time | 14 Days | 169 Days |
Enterprise Value | $1.89B | $92.83B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
MMM trades at $162.12, down 0.93% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and maintains a robust net income margin of 11.9%. Analyst consensus is mixed with a $191 price target, while recent news highlights operational turnaround progress and litigation management.
The outlook balances solid fundamentals against high debt and weak consumer demand. Upside potential exists from industrial strength and shareholder returns, but risks include cost pressures and macroeconomic headwinds. The stock's current valuation at a P/E of 28.8 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
